相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia
Oncotarget (2015)
Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis
Qi-Han Fu et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2014)
Current Approaches, Challenges and Future Directions for Monitoring Treatment Response in Prostate Cancer
T. J. Wallace et al.
JOURNAL OF CANCER (2014)
Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways
Su Jung Oh et al.
ENDOCRINE-RELATED CANCER (2012)
Design, Synthesis and Antiproliferative Activity of Novel 2-Substituted-4-amino-6-halogenquinolines
Nan Jiang et al.
MOLECULES (2012)
Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer
Caterina Peraldo-Neia et al.
BMC CANCER (2011)
Dual Inhibitors of PI3K/mTOR or mTOR-Selective Inhibitors: Which Way Shall We Go?
D. A. Sabbah et al.
CURRENT MEDICINAL CHEMISTRY (2011)
Recent Advances in Small Molecule Inhibitors of VEGFR and EGFR Signaling Pathways
Haizhen Zhong et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2011)
Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat
Xue-qing Wang et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2011)
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
V. Serra et al.
ONCOGENE (2011)
Geldanamycin and its anti-cancer activities
Yayoi Fukuyo et al.
CANCER LETTERS (2010)
Correlating Phosphatidylinositol 3-Kinase Inhibitor Efficacy with Signaling Pathway Status: In silico and Biological Evaluations
Shingo Dan et al.
CANCER RESEARCH (2010)
Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma
Saadia A. Aziz et al.
CLINICAL CANCER RESEARCH (2010)
A PHASE I/II TRIAL OF GEFITINIB GIVEN CONCURRENTLY WITH RADIOTHERAPY IN PATIENTS WITH NONMETASTATIC PROSTATE CANCER
Greetta Joensuu et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2010)
Regulation of Erk1/2 activation by osteopontin in PC3 human prostate cancer cells
Brian W. Robertson et al.
MOLECULAR CANCER (2010)
Phase II Trial of Neoadjuvant Docetaxel and Gefitinib Followed by Radical Prostatectomy in Patients With High-Risk, Locally Advanced Prostate Cancer
Jacqueline Vulky et al.
CANCER (2009)
Matrine suppresses breast cancer cell proliferation and invasion via VEGF-Akt-NF-kappa B signaling
Pengfei Yu et al.
CYTOTECHNOLOGY (2009)
Suppression of growth, migration and invasion of highly-metastatic human breast cancer cells by berbamine and its molecular mechanisms of action
Shan Wang et al.
MOLECULAR CANCER (2009)
Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer
G. Gravis et al.
ANNALS OF ONCOLOGY (2008)
Design, synthesis and in vitro antitumor activity of 4-aminoquinoline and 4-aminoquinazoline derivatives targeting EGFR tyrosine kinase
Khaled Abouzid et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2008)
A phase II clinical trial of sorafenib in androgen-independent prostate cancer
William L. Dahut et al.
CLINICAL CANCER RESEARCH (2008)
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV
S. Steinbild et al.
BRITISH JOURNAL OF CANCER (2007)
A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer
Eric J. Small et al.
BJU INTERNATIONAL (2007)
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
James A. McCubrey et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
BAY 43-9006 inhibition of oncogenic RET mutants
F Carlomagno et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Targeting mTOR signaling for cancer therapy
S Huang et al.
CURRENT OPINION IN PHARMACOLOGY (2003)
分享论文
